[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].

Takuya Hamakawa, Yukinori Kurokawa, Shuji Takiguchi, Tsuyoshi Takahashi, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Masaki Mori, Yuichiro Dok

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Combination of docetaxel, cisplatin, and S-1 (DCS) is expected as a new treatment regimen for far advanced gastric cancer. We performed DCS chemotherapy for six patients, including four cases with invasion to pancreas, three cases with para-aortic lymph node metastasis, and two cases with liver metastasis. Clinical stages were either IIIC or IV for all of the patients. The patients received 2-4 courses of docetaxel (40 mg/m2) and cisplatin (60 mg/m2) on day 1, and S-1 (80 mg/m2) on days 1-14 every 4 weeks. The response rate was 83% (5 PR and 1 SD), and the disease control rate was 100%. Grade 3/4 neutropenia, grade 3 febrile neutropenia, and grade 3 diarrhea were observed in three cases (50%), one case (17%), and one case (17%), respectively. Four of six patients underwent R0 surgery after DCS chemotherapy, and no severe complication was occurred. Histological responses were Grade 2 for two cases, Grade 1b for one case, and Grade 1a for one case, respectively. DCS regimen showed a high objective tumor response, and also is one of the promising regimens as neoadjuvant setting for far advanced gastric cancer.

Original languageEnglish
Pages (from-to)2342-2344
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume38
Issue number12
Publication statusPublished - Jan 1 2011
Externally publishedYes

Fingerprint

docetaxel
Combination Drug Therapy
Cisplatin
Stomach Neoplasms
Neoplasm Metastasis
Drug Therapy
Febrile Neutropenia
Neutropenia
Pancreas
Diarrhea
Lymph Nodes
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hamakawa, T., Kurokawa, Y., Takiguchi, S., Takahashi, T., Yamasaki, M., Miyata, H., ... Dok, Y. (2011). [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 38(12), 2342-2344.

[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer]. / Hamakawa, Takuya; Kurokawa, Yukinori; Takiguchi, Shuji; Takahashi, Tsuyoshi; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Mori, Masaki; Dok, Yuichiro.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 38, No. 12, 01.01.2011, p. 2342-2344.

Research output: Contribution to journalArticle

Hamakawa, T, Kurokawa, Y, Takiguchi, S, Takahashi, T, Yamasaki, M, Miyata, H, Nakajima, K, Mori, M & Dok, Y 2011, '[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 38, no. 12, pp. 2342-2344.
Hamakawa T, Kurokawa Y, Takiguchi S, Takahashi T, Yamasaki M, Miyata H et al. [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2011 Jan 1;38(12):2342-2344.
Hamakawa, Takuya ; Kurokawa, Yukinori ; Takiguchi, Shuji ; Takahashi, Tsuyoshi ; Yamasaki, Makoto ; Miyata, Hiroshi ; Nakajima, Kiyokazu ; Mori, Masaki ; Dok, Yuichiro. / [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer]. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2011 ; Vol. 38, No. 12. pp. 2342-2344.
@article{da1851376b8541d0815e7c05d560742f,
title = "[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].",
abstract = "Combination of docetaxel, cisplatin, and S-1 (DCS) is expected as a new treatment regimen for far advanced gastric cancer. We performed DCS chemotherapy for six patients, including four cases with invasion to pancreas, three cases with para-aortic lymph node metastasis, and two cases with liver metastasis. Clinical stages were either IIIC or IV for all of the patients. The patients received 2-4 courses of docetaxel (40 mg/m2) and cisplatin (60 mg/m2) on day 1, and S-1 (80 mg/m2) on days 1-14 every 4 weeks. The response rate was 83{\%} (5 PR and 1 SD), and the disease control rate was 100{\%}. Grade 3/4 neutropenia, grade 3 febrile neutropenia, and grade 3 diarrhea were observed in three cases (50{\%}), one case (17{\%}), and one case (17{\%}), respectively. Four of six patients underwent R0 surgery after DCS chemotherapy, and no severe complication was occurred. Histological responses were Grade 2 for two cases, Grade 1b for one case, and Grade 1a for one case, respectively. DCS regimen showed a high objective tumor response, and also is one of the promising regimens as neoadjuvant setting for far advanced gastric cancer.",
author = "Takuya Hamakawa and Yukinori Kurokawa and Shuji Takiguchi and Tsuyoshi Takahashi and Makoto Yamasaki and Hiroshi Miyata and Kiyokazu Nakajima and Masaki Mori and Yuichiro Dok",
year = "2011",
month = "1",
day = "1",
language = "English",
volume = "38",
pages = "2342--2344",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].

AU - Hamakawa, Takuya

AU - Kurokawa, Yukinori

AU - Takiguchi, Shuji

AU - Takahashi, Tsuyoshi

AU - Yamasaki, Makoto

AU - Miyata, Hiroshi

AU - Nakajima, Kiyokazu

AU - Mori, Masaki

AU - Dok, Yuichiro

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Combination of docetaxel, cisplatin, and S-1 (DCS) is expected as a new treatment regimen for far advanced gastric cancer. We performed DCS chemotherapy for six patients, including four cases with invasion to pancreas, three cases with para-aortic lymph node metastasis, and two cases with liver metastasis. Clinical stages were either IIIC or IV for all of the patients. The patients received 2-4 courses of docetaxel (40 mg/m2) and cisplatin (60 mg/m2) on day 1, and S-1 (80 mg/m2) on days 1-14 every 4 weeks. The response rate was 83% (5 PR and 1 SD), and the disease control rate was 100%. Grade 3/4 neutropenia, grade 3 febrile neutropenia, and grade 3 diarrhea were observed in three cases (50%), one case (17%), and one case (17%), respectively. Four of six patients underwent R0 surgery after DCS chemotherapy, and no severe complication was occurred. Histological responses were Grade 2 for two cases, Grade 1b for one case, and Grade 1a for one case, respectively. DCS regimen showed a high objective tumor response, and also is one of the promising regimens as neoadjuvant setting for far advanced gastric cancer.

AB - Combination of docetaxel, cisplatin, and S-1 (DCS) is expected as a new treatment regimen for far advanced gastric cancer. We performed DCS chemotherapy for six patients, including four cases with invasion to pancreas, three cases with para-aortic lymph node metastasis, and two cases with liver metastasis. Clinical stages were either IIIC or IV for all of the patients. The patients received 2-4 courses of docetaxel (40 mg/m2) and cisplatin (60 mg/m2) on day 1, and S-1 (80 mg/m2) on days 1-14 every 4 weeks. The response rate was 83% (5 PR and 1 SD), and the disease control rate was 100%. Grade 3/4 neutropenia, grade 3 febrile neutropenia, and grade 3 diarrhea were observed in three cases (50%), one case (17%), and one case (17%), respectively. Four of six patients underwent R0 surgery after DCS chemotherapy, and no severe complication was occurred. Histological responses were Grade 2 for two cases, Grade 1b for one case, and Grade 1a for one case, respectively. DCS regimen showed a high objective tumor response, and also is one of the promising regimens as neoadjuvant setting for far advanced gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84879789168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879789168&partnerID=8YFLogxK

M3 - Article

C2 - 22202376

AN - SCOPUS:84879789168

VL - 38

SP - 2342

EP - 2344

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -